Advertisement

CB1 and CB2 Receptor Pharmacology

  • Roger G. Pertwee

This review describes compounds that are currently most widely used in preclinical research to activate or block cannabinoid CB1 and CB2 receptors. Some of these compounds are ligands that display significant selectivity as CB1 or CB2 receptor agonists or antagonists, the remainder consisting of agonists each of which exhibits more or less equal potency at CB1 and CB2 receptors. The cannabinoid receptor antagonists most often used as pharmacological tools behave as inverse agonists in at least some assay systems and possible explanations for this inverse agonism are briefly discussed. Also considered in this review are actual and potential therapeutic applications for CB1 and CB2 receptor ligands.

Keywords

Inverse Agonist Glyceryl Ether Receptor Pharmacology Neutral Antagonist Receptor Inverse Agonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, Makriyannis A (1994) (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 37:1889–1893.CrossRefPubMedGoogle Scholar
  2. Bayewitch M, Rhee M-H, Avidor-Reiss T, Breuer A, Mechoulam R, Vogel Z (1996) (–)-B9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem 271:9902–9905.CrossRefPubMedGoogle Scholar
  3. Cichewicz DL (2004) Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 74:1317–1324.CrossRefPubMedGoogle Scholar
  4. Di Marzo V, Bisogno T, De Petrocellis L, Brandi I, Jefferson RG, Winckler RL, Davis JB, Dasse O, Mahadevan A, Razdan RK, Martin BR (2001) Highly selective CB1 cannabinoid receptor ligands and novel CB1/VR1 vanilloid receptor “hybrid” ligands. Biochem Biophys Res Commun 281:444–451.CrossRefPubMedGoogle Scholar
  5. Fernández-Ruiz J, González S (2005) Cannabinoid control of motor function at the basal ganglia. In: Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacology. Heidelberg:Springer-Verlag, Vol. 168, pp. 479–507.Google Scholar
  6. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161–202.CrossRefPubMedGoogle Scholar
  7. Idris AI, Van’t Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH (2005) Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 11:774–779.CrossRefPubMedGoogle Scholar
  8. Izzo AA, Coutts AA (2005) Cannabinoids and the digestive tract. In: Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacology. Heidelberg: Springer-Verlag, Vol. 168, pp. 573–598.Google Scholar
  9. Kwiatkowska M, Parker LA, Burton P, Mechoulam R (2004) A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology 174:254–259.CrossRefPubMedGoogle Scholar
  10. Le Foll B, Goldberg SR (2005) Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 312:875–883.CrossRefPubMedGoogle Scholar
  11. Leggett JD, Aspley S, Beckett SRG, D’Antona AM, Kendall DA, Kendall DA (2004) Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br J Pharmacol 141:253–262.CrossRefPubMedGoogle Scholar
  12. Leterrier C, Laine J, Darmon M, Boudin H, Rossier J, Lenkei Z (2006) Constitutive activation drives compartment-selective endocytosis and axonal targeting of type 1 cannabinoid receptors. J Neurosci 26:3141–3153.CrossRefPubMedGoogle Scholar
  13. Lu D, Meng Z, Thakur GA, Fan P, Steed J, Tartal CL, Hurst DP, Reggio PH, Deschamps JR, Parrish DA, George C, Järbe TUC, Lamb RJ, Makriyannis A (2005) Adamantyl cannabinoids: a novel class of cannabinergic ligands. J Med Chem 48:4576–4585.CrossRefPubMedGoogle Scholar
  14. Lunn CA, Fine JS, Rojas-Triana A, Jackson JV, Fan X, Kung TT, Gonsiorek W, Schwarz MA, Lavey B, Kozlowski JA, Narula SK, Lundell DJ, Hipkin RW, Bober LA (2006) A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J Pharmacol Exp Ther 316:780–788.CrossRefPubMedGoogle Scholar
  15. Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, Mechoulam R, Zimmer A, Bab I (2006) Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA 103:696–701.CrossRefPubMedGoogle Scholar
  16. Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129–180.CrossRefPubMedGoogle Scholar
  17. Pertwee RG (1999) Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6:635–664.PubMedGoogle Scholar
  18. Pertwee RG (2000) Cannabinoid receptor ligands: clinical and neuropharmacological considerations relevant to future drug discovery and development. Exp Opin Investig Drugs 9:1553–1571.CrossRefGoogle Scholar
  19. Pertwee RG (2005a) Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 76:1307–1324.CrossRefPubMedGoogle Scholar
  20. Pertwee RG (2005b) Pharmacological actions of cannabinoids. In: Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacology. Heidelberg: Springer-Verlag, Vol. 168, pp. 1–51.Google Scholar
  21. Pertwee RG (2005c) The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J 7:E625–E654.CrossRefPubMedGoogle Scholar
  22. Pertwee RG, Thomas A (2008) Therapeutic applications for agents that act at CB1 andCB2 receptors. In: Reggio P, ed. The Cannabinoid Receptors (in press).Google Scholar
  23. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D, Ferrara P, Soubrié P, Brelière JC, Le Fur G (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240–244.CrossRefPubMedGoogle Scholar
  24. Rinaldi-Carmona M, Barth F, Millan J, Derocq J-M, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B, Portier M, Shire D, Brelière J-C, Le Fur G (1998) SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284:644–650.PubMedGoogle Scholar
  25. Robson P (2005) Human studies of cannabinoids and medicinal cannabis. In: Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacology. Heidelberg: Springer-Verlag, Vol. 168, pp. 719–756.Google Scholar
  26. Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, Pertwee RG (1999a) Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br J Pharmacol 126:665–672.CrossRefPubMedGoogle Scholar
  27. Ross RA, Gibson TM, Stevenson LA, Saha B, Crocker P, Razdan RK, Pertwee RG (1999b) Structural determinants of the partial agonist-inverse agonist properties of 6R-azidohex-2–yne–8-tetrahydrocannabinol at cannabinoid receptors. Br J Pharmacol 128:735–743.CrossRefPubMedGoogle Scholar
  28. Ruiu S, Pinna GA, Marchese G, Mussinu J-M, Saba P, Tambaro S, Casti P, Vargiu R, Pani L (2003) Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor. J Pharmacol Exp Ther 306:363–370.CrossRefPubMedGoogle Scholar
  29. Savinainen JR, Järvinen T, Laine K, Laitinen JT (2001) Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB1 receptor-dependent G-protein activation in rat cerebellar membranes. Br J Pharmacol 134:664–672.CrossRefPubMedGoogle Scholar
  30. Savinainen JR, Saario SM, Niemi R, Järvinen T, Laitinen JT (2003) An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors. Br J Pharmacol 140:1451–1459.CrossRefPubMedGoogle Scholar
  31. Savinainen JR, Kokkola T, Salo OMH, Poso A, Järvinen T, Laitinen JT (2005) Identification of WIN55212–3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor. Br J Pharmacol 145:636–645.CrossRefPubMedGoogle Scholar
  32. Turu G, Simon A, Gyombolai P, Szidonya L, Bagdy G, Lenkei Z, Hunyady L (2007) The role of diacylglycerol lipase in constitutive and angiotensin AT1 receptor-stimulated cannabinoid CB1 receptor activity. J Biol Chem 282:7753–7757.CrossRefPubMedGoogle Scholar
  33. Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, Mark L, Pearson MS, Miller W, Shan S, Rabadi L, Rotshteyn Y, Chaffer SM, Turchin PI, Elsemore DA, Toth M, Koetzner L, Whiteside GT (2005) Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48:658–672.CrossRefPubMedGoogle Scholar
  34. Yao BB, Mukherjee S, Fan Y, Garrison TR, Daza AV, Grayson GK, Hooker BA, Dart MJ, Sullivan JP, Meyer MD (2006) In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? Br J Pharmacol 149:145–154.CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Roger G. Pertwee
    • 1
  1. 1.Institute of Medical SciencesUniversity of AberdeenScotlandUK

Personalised recommendations